Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
48 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Lecanemab in Early Alzheimer's Disease.
van Dyck CH, Swanson CJ, Aisen P, et al. · N Engl J Med · 2023Clinical Trial, Phase III, Multicenter Study
- Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
Honig LS, Sabbagh MN, van Dyck CH, et al. · Alzheimers Res Ther · 2024Multicenter Study, Randomized Controlled Trial
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Swanson CJ, Zhang Y, Dhadda S, et al. · Alzheimers Res Ther · 2021Clinical Trial, Phase II, Randomized Controlled Trial
- Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study.
van Dyck CH, Sperling R, Johnson K, et al. · Alzheimers Dement · 2025Randomized Controlled Trial
- The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
Wu W, Ji Y, Wang Z, et al. · Eur J Med Res · 2023Meta-Analysis, Systematic Review
- Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis.
Ebell MH, Barry HC, Baduni K, et al. · Ann Fam Med · 2024Meta-Analysis, Systematic Review
- Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
McDade E, Cummings JL, Dhadda S, et al. · Alzheimers Res Ther · 2022Randomized Controlled Trial, Clinical Trial, Phase II
- Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis.
Arroyo-Pacheco N, Sarmiento-Blanco S, Vergara-Cadavid G, et al. · Ageing Res Rev · 2025Systematic Review, Meta-Analysis
- Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
Chowdhury S, Chowdhury NS · Int J Immunopathol Pharmacol · 2023Systematic Review
- The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis.
Hsu CW, Hsu TW, Kao YC, et al. · J Prev Alzheimers Dis · 2025Comparative Study, Meta-Analysis
- Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer's disease: A systematic review and meta-analysis.
Shim GH, Lau ECY, Huynh ALH, et al. · Ageing Res Rev · 2026Systematic Review, Meta-Analysis
- A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's disease.
Chhabra A, Solanki S, Saravanabawan P, et al. · Expert Opin Biol Ther · 2024Systematic Review
- Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease.
Chen C, Katayama S, Lee JH, et al. · J Prev Alzheimers Dis · 2025Clinical Trial, Phase III, Multicenter Study
- Safety profiles of lecanemab: A systematic review and meta-analysis of randomized controlled trials and real-world evidence.
Qi L, Zheng F, Tu M, et al. · J Prev Alzheimers Dis · 2026Systematic Review, Meta-Analysis
- Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
Qiao Y, Gu J, Yu M, et al. · CNS Drugs · 2024Systematic Review, Research Support, Non-U.S. Gov't
- Comparisons of efficacy and safety of immunotherapies for Alzheimer's disease treatment: A network meta-analysis of randomised controlled trials.
Su CH, Chang YT, Tseng HS, et al. · Clin Med (Lond) · 2025Network Meta-Analysis, Systematic Review
- Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease.
Nonino F, Minozzi S, Sambati L, et al. · Cochrane Database Syst Rev · 2026Systematic Review, Meta-Analysis
- Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.
Logovinsky V, Satlin A, Lai R, et al. · Alzheimers Res Ther · 2016Multicenter Study, Randomized Controlled Trial
- TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease.
Salloway S, Pain A, Lee E, et al. · Alzheimers Dement · 2025Clinical Trial, Phase III, Randomized Controlled Trial
- Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease.
Cohen S, van Dyck CH, Gee M, et al. · J Prev Alzheimers Dis · 2023Clinical Trial, Phase III, Randomized Controlled Trial
- Pharmacologic and Nutritional Interventions for Early Alzheimer's Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Zeng B, Tang C, Wang J, et al. · J Alzheimers Dis · 2024Systematic Review, Network Meta-Analysis
- Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer's disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness.
Avgerinos KI, Manolopoulos A, Ferrucci L, et al. · Sci Rep · 2024Systematic Review, Meta-Analysis
- Combining CSF MTBR-tau243 and plasma pTau217 ratio enhances the prediction of continuous regional tau PET burden in early Alzheimer's disease.
Devanarayan V, Horie K, Wildsmith K, et al. · Alzheimers Dement · 2025Clinical Trial, Phase III, Multicenter Study
- Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes.
Perry R, Kipps C, Soto Martín ME, et al. · J Prev Alzheimers Dis · 2026Randomized Controlled Trial, Multicenter Study
- Real-world safety and efficacy of lecanemab in the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Wu Y, Zhu L, Chen J, et al. · J Neurol · 2026Systematic Review, Meta-Analysis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.